Milestone Scientific Overhauls Board for Growth Phase
Event summary
- Milestone Scientific transitions Benedetta I. Casamento from Chair to Executive Chair on June 25, 2026.
- Company adds Greg Shilling and Kelly Ann Ulto as independent directors with healthcare tech and finance expertise.
- Founder Leonard Osser restructures agreement to continue advisory role, aligning shareholder interests.
The big picture
Milestone Scientific’s board overhaul reflects a strategic pivot to strengthen governance and align leadership with growth objectives. The additions of healthcare tech and finance experts signal a focus on disciplined execution, while the founder’s restructured role aims to balance continuity with shareholder interests. This move comes as the company seeks to advance its painless injection technology in an increasingly competitive medical device market.
What we're watching
- Governance Dynamics
- How the new board composition will influence Milestone’s strategic execution and innovation focus.
- Founder Influence
- Whether Leonard Osser’s continued advisory role maintains sufficient continuity amid governance changes.
- Growth Trajectory
- The pace at which Milestone can scale its drug delivery technology with the enhanced board leadership.
Related topics